Israeli company Baby's Breath Ltd. has developed the Child Hood for the delivery of aerosol medications to babies and toddlers. Unlike the conventional inhalation face-masks used today with babies suffering from asthma or similar conditions, the Child Hood does not require near-total immobility during drug administration. Such immobility is generally needed in order to ensure that the mask remains sealed on the baby's face, in order to deliver the drug directly to the baby's nose. However, the Child Hood safely and comfortably encloses the baby's head, without any contact, while delivering the necessary dosage of medication close to the baby's nose. It is equipped with a special adapter to accommodate the output of an aerosol generator (nebulizer) and similar drug delivery systems.
As reported by David Brinn of the ISRAEL21c website, "Aerosol therapy for wheezy infants using such a nebulizer hood has proven to be very efficient and preferred by parents, is much better tolerated by infants and simpler to operate. The medication can be administered even when a child is asleep."
Baby Breath's Child Hood was developed by Dr. Israel Amirav, a pediatrician at Sieff Hospital in Tzfat (Safed) in the north of Israel, Dr. David Katoshevski of Ben-Gurion University's department of biotechnology and environmental engineering, his master's degree student Tal Shaked, and Dr. David Broday of the Technion in Haifa.
Dr. Katoshevski told Israel21c, "The motivation behind the Child Hood is the fact that the mask, which people usually use for inhalation, is not convenient, not effective and not tolerated by infants and small children. They scream, move around and much of the medicine is lost. With the Child Hood, small children up to the age of one can get their medication administered during their sleep, and it's user friendly for the parent and the doctor."
The Child Hood is due out on the Israeli market by 2005, with future plans to sell to the US medical market as well.
As reported by David Brinn of the ISRAEL21c website, "Aerosol therapy for wheezy infants using such a nebulizer hood has proven to be very efficient and preferred by parents, is much better tolerated by infants and simpler to operate. The medication can be administered even when a child is asleep."
Baby Breath's Child Hood was developed by Dr. Israel Amirav, a pediatrician at Sieff Hospital in Tzfat (Safed) in the north of Israel, Dr. David Katoshevski of Ben-Gurion University's department of biotechnology and environmental engineering, his master's degree student Tal Shaked, and Dr. David Broday of the Technion in Haifa.
Dr. Katoshevski told Israel21c, "The motivation behind the Child Hood is the fact that the mask, which people usually use for inhalation, is not convenient, not effective and not tolerated by infants and small children. They scream, move around and much of the medicine is lost. With the Child Hood, small children up to the age of one can get their medication administered during their sleep, and it's user friendly for the parent and the doctor."
The Child Hood is due out on the Israeli market by 2005, with future plans to sell to the US medical market as well.